Outlook Therapeutics EBIT

Outlook Therapeutics (OTLK) currently reports a EBIT of $-47T as of March 2026. That compares with $-110T in the prior-year period — up 56.9% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Outlook Therapeutics's EBIT history and peer comparisons.

Outlook Therapeutics's EBIT increased from $-110T to $-47T — a 56.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Outlook Therapeutics's EBIT of $-47T is lower than the Healthcare sector average of $23B. That is roughly 202172.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Outlook Therapeutics reported $-47T in EBIT as of March 2026. That compares with $-110T in the prior-year period — up 56.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-47T, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Outlook Therapeutics, and consider following OTLK for alerts when major investors trade the stock.